Aetion Announces $36 Million in Series B Funding to Accelerate Its Platform for the Analysis of Real-World Evidence to Biopharma Companies and Health Care Payers
Home » Aetion Announces $36 Million in Series B Funding to Accelerate Its Platform for the Analysis of Real-World Evidence to Biopharma Companies and Health Care Payers
Aetion Announces $36 Million in Series B Funding to Accelerate Its Platform for the Analysis of Real-World Evidence to Biopharma Companies and Health Care Payers2018-04-112018-04-13http://redpeppermergers.com/wp-content/uploads/rpm-white-red-1.pngRedPepper Mergershttp://redpeppermergers.com/wp-content/uploads/rpm-white-red-1.png200px200px
VIEW ARTICLE If you would like to know more regarding the topic in this blog post, please do not hesitate to contact us.